Research statistics

Maridebart cafraglutide research: publications and trials

What has been published on Maridebart cafraglutide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Maridebart cafraglutide works or is safe. For what it is and what the studies found, see the Maridebart cafraglutide profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

11

Since 2024

Publications in 2026 so far

3

Through November 15, 2026

Human clinical research

18.2%

2 of 11 classified

Registered clinical trials

32

ClinicalTrials.gov

Randomized controlled trials

2

Publications reporting an RCT in people

Systematic reviews and meta-analyses

0

Preclinical studies

9.1%

1 animal · 0 in vitro · 0 computational

Records that only mention it

18

Not counted above

Status in the library: In clinical trials. Groups: GLP-1 receptor agonists.

What to keep in mind

  • Fewer than three randomized controlled trials are indexed.
  • Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.
  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Maridebart cafraglutide publications by year and evidence

2024, Human clinical research: 1 of 32024, Other and not yet classified: 2 of 32025, Human clinical research: 1 of 52025, Reviews and meta-analyses: 1 of 52025, Other and not yet classified: 3 of 52026 (to date), Preclinical (animal, in vitro, computational): 1 of 32026 (to date), Reviews and meta-analyses: 2 of 3Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified0246202420252026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
202410023
202510135
2026 (to date)01203

Study types

Editorial, letter or other5
Review3
Randomized controlled trial2
Animal study1

Research areas

From MeSH major topics. A paper can be in several areas.

Obesity and weight management7
Metabolic health6
Endocrinology2
Antimicrobial and infectious disease1
Immune system1
Neurological and mental health1
Oncology1

Registered clinical trials

5 of 7 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 13 · Active, not recruiting: 10 · Recruiting: 7 · Not yet recruiting: 2
Phase 1: 17 · Phase 2: 3 · Phase 3: 12

TrialStatusPhaseStartedResults
Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)NCT07908316 · 180 enrolledRecruitingPhase 12026-11—
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple DosesNCT07921316 · 356 enrolledNot yet recruitingPhase 12026-11—
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesNCT07866066 · 1,300 enrolledRecruitingPhase 32026-10—
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or OverweightNCT07871409 · 230 enrolledRecruitingPhase 32026-10—
Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous DoseNCT07832799 · 340 enrolledNot yet recruitingPhase 12026-10—
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)NCT07684144 · 950 enrolledRecruitingPhase 32026-07—
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)NCT07684235 · 3,200 enrolledRecruitingPhase 32026-07—
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)NCT07575399 · 300 enrolledRecruitingPhase 32026-05—
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityNCT07523711 · 49 enrolledActive, not recruitingPhase 12026-04—
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightNCT07441252 · 180 enrolledActive, not recruitingPhase 22026-03—
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyNCT07225686 · 250 enrolledActive, not recruitingPhase 32025-12—
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous PresentationsNCT07313761 · 349 enrolledCompletedPhase 12025-12—
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyNCT07226765 · 250 enrolledActive, not recruitingPhase 32025-11—
Effect of Maridebart Cafraglutide on the Heart's Electrical ActivityNCT07229157 · 81 enrolledCompletedPhase 12025-10—
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) PresentationsNCT07226778 · 348 enrolledCompletedPhase 12025-10—
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusNCT07160257 · 56 enrolledActive, not recruitingPhase 12025-08—
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 · 12,800 enrolledActive, not recruitingPhase 32025-07—
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 · 5,056 enrolledRecruitingPhase 32025-06—
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity DiseaseNCT06987695 · 279 enrolledActive, not recruitingPhase 32025-06—
The Effect of AMG 133 on Gastric EmptyingNCT07429032 · 57 enrolledCompletedPhase 12025-04—
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858878 · 1,105 enrolledActive, not recruitingPhase 32025-03—
A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic FunctionNCT07428525 · 36 enrolledCompletedPhase 12025-03—
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 · 3,853 enrolledActive, not recruitingPhase 32025-03—
A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the BodyNCT07429045 · 44 enrolledCompletedPhase 12025-03—
A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or ObesityNCT07310563 · 59 enrolledCompletedPhase 12024-12—
A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or ObesityNCT07717814 · 154 enrolledCompletedPhase 12024-11—
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)NCT06660173 · 409 enrolledActive, not recruitingPhase 22024-11—
A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or ObesityNCT06976372 · 120 enrolledCompletedPhase 12024-08—
A Study to Evaluate AMG 133 in Chinese Participants With Obesity or OverweightNCT06352892 · 20 enrolledCompletedPhase 12024-04—
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes MellitusNCT05669599 · 592 enrolledCompletedPhase 22023-01—
Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian ParticipantsNCT05056246 · 34 enrolledCompletedPhase 12021-09Posted
Single and Multiple Ascending Dose Study of AMG 133 in Participants With ObesityNCT04478708 · 110 enrolledCompletedPhase 12020-08Posted

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.

    The New England journal of medicine · June 23, 2025 · Randomized controlled trial · cited 105 times

    PMID 40549887 · DOI 10.1056/nejmoa2504214 · Human clinical research

  2. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.

    Nature metabolism · February 5, 2024 · Randomized controlled trial · cited 216 times · open access

    PMID 38316982 · DOI 10.1038/s42255-023-00966-w · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.

    Nature metabolism · February 5, 2024 · Randomized controlled trial · cited 216 times · open access

    PMID 38316982 · DOI 10.1038/s42255-023-00966-w · Human clinical research

  2. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.

    The New England journal of medicine · June 23, 2025 · Randomized controlled trial · cited 105 times

    PMID 40549887 · DOI 10.1056/nejmoa2504214 · Human clinical research

  3. Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.

    Endocrine reviews · March 1, 2026 · Review · cited 37 times

    PMID 41054801 · DOI 10.1210/endrev/bnaf036 · Reviews and meta-analyses

  4. The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs.

    Journal of clinical medicine · May 29, 2025 · Review · cited 12 times · open access

    PMID 40507574 · DOI 10.3390/jcm14113812 · Reviews and meta-analyses

  5. Antagonizing GIPR adds fire to the GLP-1R flame.

    Trends in endocrinology and metabolism: TEM · May 18, 2024 · Editorial, letter or other · cited 11 times · open access

    PMID 38763780 · DOI 10.1016/j.tem.2024.04.016 · Commentary and other

Latest publications

  1. Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.

    Antibody therapeutics · June 1, 2026 · Review · cited 1 times · open access

    PMID 42592044 · DOI 10.1093/abt/tbag029 · Reviews and meta-analyses

  2. Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity.

    Journal of medicinal chemistry · April 6, 2026 · Animal study · cited 3 times · open access

    PMID 41941715 · DOI 10.1021/acs.jmedchem.6c00032 · Animal studies

  3. Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.

    Endocrine reviews · March 1, 2026 · Review · cited 37 times

    PMID 41054801 · DOI 10.1210/endrev/bnaf036 · Reviews and meta-analyses

  4. Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial.

    The New England journal of medicine · December 1, 2025 · Editorial, letter or other · cited 1 times

    PMID 41337722 · DOI 10.1056/nejmc2514331 · Commentary and other

  5. Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply.

    The New England journal of medicine · December 1, 2025 · Editorial, letter or other · cited 2 times

    PMID 41337724 · DOI 10.1056/nejmc2514331 · Commentary and other

  6. Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial.

    The New England journal of medicine · December 1, 2025 · Editorial, letter or other · cited 0 times

    PMID 41337723 · DOI 10.1056/nejmc2514331 · Commentary and other

  7. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.

    The New England journal of medicine · June 23, 2025 · Randomized controlled trial · cited 105 times

    PMID 40549887 · DOI 10.1056/nejmoa2504214 · Human clinical research

  8. The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs.

    Journal of clinical medicine · May 29, 2025 · Review · cited 12 times · open access

    PMID 40507574 · DOI 10.3390/jcm14113812 · Reviews and meta-analyses

  9. Antagonizing GIPR adds fire to the GLP-1R flame.

    Trends in endocrinology and metabolism: TEM · May 18, 2024 · Editorial, letter or other · cited 11 times · open access

    PMID 38763780 · DOI 10.1016/j.tem.2024.04.016 · Commentary and other

  10. Phase I results for AMG 133.

    Nature reviews. Endocrinology · April 1, 2024 · Editorial, letter or other · cited 6 times

    PMID 38388678 · DOI 10.1038/s41574-024-00967-z · Commentary and other

Browse all 11 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: AMG 133; Maridebart cafraglutide; MariTide

((TITLE_ABS:"AMG 133" OR CHEM:"AMG 133" OR TITLE_ABS:"AMG133" OR CHEM:"AMG133") OR (TITLE_ABS:"Maridebart cafraglutide" OR CHEM:"Maridebart cafraglutide") OR (TITLE_ABS:"MariTide" OR CHEM:"MariTide")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Maridebart cafraglutide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/maridebart-cafraglutide